PGD NGS – Multiple biopsies are no longer needed!
Conventional approach to embryonic genetic evaluation required a number of independent methods (e.g. FISH, PCR, micro-arrays) to be used in order to investigate different embryo parameters. In consequence, multiple biopsies, resulting in decrease of embryo’s viability, may be needed. Preimplantation Genetic Diagnosis in INVICTA Genetic Laboratory uses NGS technique (Next Generation Sequencing) which is the first comprehensive clinical approach to preimplantation genetic diagnosis of monogenetic disease, aneuploidy testing and sex determination simultaneously. Multiple biopsies are no longer needed, thus eliminating unnecessary risks to embryo’s viability.
Biopsy is an invasive procedure and should be considered as harmful for developing embryo. Although there is no evidence that properly conducted biopsy is a threat to embryo’s viability, it is a manual based procedure with the case-to-case variety of outcome. Therefore the number of biopsies from given embryo should be reduced as much as possible. The Reproduction Societies all over the world are in agreement about this issue.
Use of the Next Generation Sequencing approach in the preimplantation genetic diagnosis at INVICTA has allowed our experts to develop a unique single-plot protocol with multi-directional analysis that require only a single biopsy. Not only we use cutting-edge technology in the field of PGD but we went further and designed and introduced in clinical IVF-PGD procedure innovative protocol adjusted to single biopsy. We focus our efforts on achieving an increase of IVF reproduction success rate.
INVICTA PGS NGS 360oTM provides aneuploidy screening for all autosomal chromosomes and sex chromosomes, with the possibility of diagnosis of Robertsonian translocation at the same time. INVICTA PGD ONETM offers possibility of diagnosis any single gene disorder with established genetic background regardless of inheritance mechanism (dominant, recessive, sex-linked), population frequency (common disease, orphan disease), type of causative mutation (e.g. point mutation, polynucleotide deletions and insertions, exon deletions and duplications, inversions, microdeletions, translocations). Moreover, INVICTA PGD ONE is not limited with the number of mutation diagnosed in a couple preparing for IVF-PGD. INVICTA PGS NGS 360oTM and INVICTA PGD ONETM can be performed simultaneously, meaning minimum genetic risk with maximum performance security with only one biopsy.
Additional advantage for IVF clinic and its patients is a comprehensive report with the summary of all preimplantation diagnosis and concluded with transfer recommendations for each embryo that considers all genetic information gathered during PGD. This report facilitates the entire IVF-PGD process even more by providing clear information needed by patients and their doctors to make well informed decisions.
Today’s innovative technologies allow us to determine the maximum information from the minimum sample. In the IVF field a security of the developing embryo is of utmost priority and with PGS NGS 360oTM and PGD ONETM we have the tools to minimize the risks and provide our patients with the highest chances for successful reproduction.
INVICTA Genetic Laboratory is your trustworthy PGD NGS service provider.